11/25
09:06 am
vor
Vor Biopharma (NASDAQ:VOR) had its "neutral" rating reaffirmed by analysts at Wedbush. They now have a $9.00 price target on the stock.
Medium
Report
Vor Biopharma (NASDAQ:VOR) had its "neutral" rating reaffirmed by analysts at Wedbush. They now have a $9.00 price target on the stock.
11/25
09:06 am
vor
Vor Biopharma (NASDAQ:VOR) had its "neutral" rating reaffirmed by analysts at Wedbush. They now have a $9.00 price target on the stock.
Medium
Report
Vor Biopharma (NASDAQ:VOR) had its "neutral" rating reaffirmed by analysts at Wedbush. They now have a $9.00 price target on the stock.
11/25
09:04 am
vor
Rating for VOR
Medium
Report
Rating for VOR
11/25
09:04 am
vor
Rating for VOR
Medium
Report
Rating for VOR
10/15
08:12 am
vor
Vor Biopharma (NASDAQ:VOR) was upgraded by analysts at Robert W. Baird from a "neutral" rating to an "outperform" rating. They now have a $64.00 price target on the stock, up previously from $20.00.
Medium
Report
Vor Biopharma (NASDAQ:VOR) was upgraded by analysts at Robert W. Baird from a "neutral" rating to an "outperform" rating. They now have a $64.00 price target on the stock, up previously from $20.00.
10/15
06:34 am
vor
Rating for VOR
Medium
Report
Rating for VOR
10/15
06:34 am
vor
Rating for VOR
Medium
Report
Rating for VOR
10/14
05:10 pm
vor
Vor Bio upgraded to Outperform from Neutral at Baird
Medium
Report
Vor Bio upgraded to Outperform from Neutral at Baird
10/14
05:10 pm
vor
Vor Bio upgraded to Outperform from Neutral at Baird
Medium
Report
Vor Bio upgraded to Outperform from Neutral at Baird
9/24
08:06 am
vor
Vor Biopharma (NYSE:VOR) was upgraded by analysts at Stifel Nicolaus from a "hold" rating to a "buy" rating. They now have a $55.00 price target on the stock.
Medium
Report
Vor Biopharma (NYSE:VOR) was upgraded by analysts at Stifel Nicolaus from a "hold" rating to a "buy" rating. They now have a $55.00 price target on the stock.
9/24
08:06 am
vor
Vor Biopharma (NYSE:VOR) was upgraded by analysts at Stifel Nicolaus from a "hold" rating to a "buy" rating. They now have a $55.00 price target on the stock.
Medium
Report
Vor Biopharma (NYSE:VOR) was upgraded by analysts at Stifel Nicolaus from a "hold" rating to a "buy" rating. They now have a $55.00 price target on the stock.
9/23
08:56 pm
vor
Vor Bio upgraded to Buy from Hold at Stifel
Medium
Report
Vor Bio upgraded to Buy from Hold at Stifel